Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetraspan vs Ringer's Acetate as CPB Prime in CABG
NCT01511120Phase 2Completed
- Sponsor
- Haukeland University Hospital
- Start
- Nov 2011
- Primary completion
- Dec 2013
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydroxyethyl starch 130/0.42 in coronary artery disease (CAD) (2 arms), sponsored by Haukeland University Hospital. Primary endpoint: Reduction of organ edema and improved organ function. Started Nov 2011; status: completed.
02
Drugs
hydroxyethyl starch 130/0.42
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01511120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511120.